Quality of Life in Acute Complicated and Chronic Recurrent Left-sided Diverticulitis

NCT ID: NCT05942833

Last Updated: 2025-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

136 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-16

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients presenting in hospital with symptoms of acute diverticulitis. Acute inflammation of the left-sided colon is confirmed with CT scan or ultrasound in experienced centers and diagnosis is defined according to the "Classification of Diverticular Disease (CDD)". CDD Type 2a, 2b and 3b will be included and then randomized in two groups. Group A will get an early left hemicolectomy 7 to 10 days after admission and initial antibiotic therapy and/or drainage of the abscess. Group B is designated for an elective resection 6 to 8 weeks after dismissal at the earliest and initial conservative treatment and/or after drainage of the abscess. Six weeks after the operation patients of Group A will be asked for their present quality of life with a standardized scoring system (Gastrointestinal Quality of Life Index = GIQLI; Short-form 36 Score = SF-36 Score; Low anterior resection syndrome = LARS Score). Group B (elective resection) will be asked at their readmission prior to elective surgery is done. This survey package will be repeated again 6 to 8 weeks later in both groups. Primary endpoints will be the two GIQLI at the said examination times. Secondary endpoints will be SF-36 score, LARS-score, GIQLI-Domains, anastomosis insufficiency and other complications, mortality and length of hospital stay. Comparisons between the groups are made at the said examination times but also 6-8 weeks after the operation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary endpoints:

Gastrointestinal Quality of Life Index (GIQLI)

Secondary endpoints:

SF-36 score (physical and mental health summary scores), LARS score, GIQLI-domains, anastomosis insufficiency and other complications, exitus and length of hospital stay

Treatment strategy:

A patient is coming into the hospital with acute symptoms of diverticulitis. The diagnosis must then be confirmed either with ultrasound or with a CT scan. After confirmation the patient is asked to be part of the study. At that point of time the patient does not know his randomization. After the patient's approval and signed consent the patients will bei informed about the further procedure and the appointment of surgery. Questionnaires will now be filled out and antibiotical treatment starts. If necessary a radiological intervention (drainage) is performed.

Is the patient is randomized into Group A he will get early left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage). If the patient is in Group B he will receive an elective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage).

Reassessment of the questionnaires will bei done in both groups. Group A will be asked 6-8 after surgery and again 6-8 weeks after the second reassessment.

Group B will be asked 6-8 weeks after discharge (directly before surgery) and again 6-8 weeks after surgery.

The aim of the study is to evaluate the outcome and quality of life in patients receiving early surgery versus elective resection of the left-sided colon in acute complicated diverticulitis and chronic recurrent diverticulitis with acute exacerbation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diverticulitis of Sigmoid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective, randomized controlled
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A (Early)

Early left hemicolectomy immediately up to a maximum of 2 days after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis

Group Type EXPERIMENTAL

Sigmoid resection

Intervention Type PROCEDURE

Timing of sigmoid resection

Group B (Late)

Elective left hemicolectomy 6 to 8 weeks after 7-10 days lasting initial conservative or interventional treatment (e.g: antibiotics, analgesics, drainage) and CT scan/ultrasound proven left-sided colonic diverticulitis

Group Type OTHER

Sigmoid resection

Intervention Type PROCEDURE

Timing of sigmoid resection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sigmoid resection

Timing of sigmoid resection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent to participate in the study
* CDD Type 2a, 2b: acute complicated left-sided diverticulitis
* CDD Type 3b: relapsing diverticulitis without complications (\>2 episodes within 2 years)
* Acute presentation
* Inflammation located in the left-sided colon
* Inflammation is CT proven or ultrasound confirmed from experienced radiologists

Exclusion Criteria

* \< 18 years
* Pregnancy
* BMI \> 55kg/m2
* Current colorectal carcinoma in the left-sided colon
* Oral and/or intravenous corticosteroid
* Ongoing chemotherapy
* Status post left hemicolectomy
* Patients who cannot take care of themselves at home or are unable to follow instructions
* Patients who are not fit for surgery (anesthesia, expert knowledge from specialists) and will not benefit from surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Krankenhaus Barmherzige Schwestern Linz

OTHER

Sponsor Role collaborator

Elisabethinen Hospital

OTHER

Sponsor Role collaborator

Universitätsmedizin Mannheim

OTHER

Sponsor Role collaborator

Kepler University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Shamiyeh, Dr.

Role: PRINCIPAL_INVESTIGATOR

Kepler University Hospital Linz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ordensklinikum Elisabethinen Linz

Linz, Austria, Austria

Site Status RECRUITING

Krankenhaus Barmherzige Schwestern Linz

Linz, Upper Austria, Austria

Site Status RECRUITING

Kepler University Hospital

Linz, Upper Austria, Austria

Site Status RECRUITING

Universitätsklinikum Mannheim

Mannheim, Mannheim, Germany

Site Status NOT_YET_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sandra Raab, Dr.

Role: CONTACT

+43 (0)5 7680 83 - 78470

Andreas Shamiyeh, Dr.

Role: CONTACT

+43 (0)5 7680 83 - 2133

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Matthias Biebl, Dr.

Role: primary

+43 (0)732-7677 - 7300

Christoph Schwaiger-Hengstschläger, Dr.

Role: backup

+43 (0)732-7677 - 7300

Matthias Biebl, Dr.

Role: primary

+43 (0)732-7677 - 7300

Gerd Pressl, Dr.

Role: backup

+43 732 7677 - 7300

Sandra Raab, Dr.

Role: primary

+43 (0)5 7680 83 - 78470

Andreas Shamiyeh, Dr.

Role: backup

+43 (0)5 7680 83 - 2133

Steffen Seyfried, PD MD

Role: primary

+49 621 383-4864

Christoph Reißfelder, Prof. MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1203/2022

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Pro-Chol Study
NCT07245108 RECRUITING